McMillan BJ, Tibbe C, Drabek AA, et al. Structural basis for regulation of ESCRT-III complexes by Lgd. Cell Rep. 2017;19(9):1750-1757.
McMillan BJ, Zimmerman B, Egan ED, et al. Structure of human POFUT1, its requirement in ligand-independent oncogenic Notch signaling, and functional effects of Dowling-Degos mutations. Glycobiology. 2017;17:1-10.
McMillan BJ, Schnute B, Ohlenhard N, et al. A tail of two sites: a bipartite mechanism for recognition of notch ligands by mind bomb E3 ligases. Mol Cell. 2015;57(5):912-924.
Brian McMillan, Ph.D.
Brian McMillan is a senior scientist I and a member of the biochemistry team, led by Virendar Kaushik, in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. At CDoT, he leads an oncology drug discovery project team and provides protein structure/function expertise for other therapeutics projects. His primary role in CDoT is the design and execution of in vitro assays for high-throughput screening and validation. McMillan also has an extensive background in crystallography and supports structure-based drug design for multiple projects.
Prior to joining the Broad Institute in 2016, McMillan completed postdoctoral training in the laboratory of Stephen Blacklow at Harvard Medical School. At HMS, he has also held the position of instructor since 2015. Before embarking on his postdoc, McMillan worked in industry at Invitrogen, producing and validating cell lines for high-throughput screening of drug discovery libraries.
McMillan obtained a Ph.D. in cancer biology at the University of Wisconsin–Madison, working in the laboratory of Christopher Bradfield. He also holds a B.S. in molecular biology from the University of Illinois at Urbana-Champaign.
Contact Brian McMillan via email at email@example.com.